Signifier Medical Technologies (previously known as Snoozeal), a London, UK-based sleep disordered breathing company, closed a Series B funding.
The round was led by The Pritzker Organization, with participation from the family office of Robert Parkinson Jr, the former Chairman and CEO of Baxter International, and participation from existing investors.
With this round, Signifier has raised a total in excess of $13 million since its founding in 2015.
The company intends to use the funds to
– accelerate the data generation in on-going clinical trials with its innovative ‘Snoozeal’ neurostimulation device to address snoring and mild obstructive sleep apnoea (OSA)
– complete the FDA approval process, with de novo filing anticipated in H2 2019
– further invest in expanding its product range, including adding advanced analytics capabilities, and
– expand the team to broaden its capability set, including commercial readiness in key geographies.
Led by Prof. Anshul Sama, co-founder and Chief Medical Officer, Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.
In conjunction with the closing of the Series B round:
– Mr Steffen Kastner, former Managing Director of Goldman Sachs, where he co-headed its credit investing business in Europe; and
– Mr Robert Sullivan, former CEO, COO and founder of Capital Holdings and current Regional President of Fifth Third Bancorp,
join Mr Kieran Gallahue (Chairman) on the Board.